BioSpace News Archive

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the company’s management is scheduled to present at the 2020 Baird Global Healthcare Conference. Brad Gray, president and chief executive officer, is scheduled to present on Wednesday, September 9th, 2020 at 2:35pm ET. Interested parties can access the live webcast with accompa

-- New Three-Year Gene Therapy Data for Parkinson’s Disease Part of 30 Abstracts to be Presented at 2020 Psych Congress and the MDS Virtual Congress 2020 -- - INGREZZA® (valbenazine) Data Analyses from Long-Term Phase III Studies Demonstrate Sustained Clinical Benefit, Safety and Tolerability in Patients with Tardive Dyskinesia - New Phase III Data Analyses of ONGENTYS® (opicapone) Support Treatment as Add-On Therapy to Levodopa/Carbidopa for Parkinson’s Patients with Motor F

CONMED Corporation announced that Curt R. Hartman, President, Chief Executive Officer and Chair of the Board, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference at 3:30 p.m. ET on Wednesday, September 16, 2020.

CooperCompanies (NYSE: COO) today announced financial results for its fiscal third quarter ended July 31, 2020. Revenue decreased 15% year-over-year to $578.2 million. CooperVision (CVI) revenue down 12% to $449.3 million, and CooperSurgical (CSI) revenue down 24% to $128.9 million. GAAP diluted earnings per share $1.12, down $1.28 or 53% from last year’s third quarter. Non-GAAP diluted earnings per share $2.28, down $0.95 or 30% fr

New Phase 1b Data of Investigational Gene Therapy Compound, VY-AADC (NBIb-1817), Evaluating Three-Year Safety and Clinical Outcomes in Patients with Advanced Parkinson’s Disease Voyager to Participate in Upcoming September Investor Conferences CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced data presentation

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will participate in a fireside chat at the Citi 15 th Annual Biopharma Virtual Conference on Thursday, September 10, 2020 at 11:40 a.m. ET / 8:40 a.m. PT . Dan Faga, Executive Vice President and Chief Operating Officer, wil

3D technology has come up as a blessing for the health care sectors as it application is seen in defense, architecture, gaming, and heath care.

Hutchison China MediTech Limited has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth factor receptors, in patients with advanced intrahepatic cholangiocarcinoma, which is a type of liver cancer.

The global heparin market is anticipated to attract growth opportunities on the back of the rising count of surgical procedures and increasing treatment of venous thromboembolism including pulmonary embolism and deep vein thrombosis.

Cannabis sativa, Cannabis indica, and Cannabis ruderalis are referred as cannabis or marijuana and used for medicinal, recreational, and ritualistic purposes.